Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.

@article{Oka2017WilmsTG,
  title={Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.},
  author={Y. Oka and Akihiro Tsuboi and Jun Nakata and Sumiyuki Nishida and Naoki Hosen and Atsushi Kumanogoh and Yusuke Oji and Haruo Sugiyama},
  journal={Oncology research and treatment},
  year={2017},
  volume={40 11},
  pages={682-690}
}
The identification of human Wilms' tumor gene 1 (WT1) protein-derived cytotoxic T lymphocyte (CTL) epitopes and the in vivo efficacy of WT1 peptide-based immunotherapy in a mouse model were reported in 2000. This successful basic research led to clinical studies of a WT1 peptide vaccine, and a positive impact on clinical response was first demonstrated in 2003 in the form of a reduction in blast cells of vaccine-treated patients with myelodysplastic syndromes (MDS). Since then, data on WT1… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
1 Citations
44 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 44 references

DSP-7888, a novel cocktail design of WT1 peptide vaccine, and its combinational immunotherapy with immune checkpoint-blocking antibody against PD-1

  • M Gotoh, M Nakamura, +4 authors CJ Li
  • Blood
  • 2016

Prelimi - nary results from a phase 1 / 2 study of DSP - 7888 , a novel WT 1 peptide - based vaccine , in patients with myelodysplastic syndrome ( MDS )

  • F Fujiki, Y Oka, +15 authors H Sugiyama
  • Blood
  • 2016

PD - 1 blockade with nivolumab in relapsed or refractory Hodgkin ’ s disease

  • SM Ansell, AM Lesokhin, +15 authors MA Shipp
  • N Engl J Med
  • 2015

Similar Papers

Loading similar papers…